See more : Highwoods Properties, Inc. (HIW) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CGift AG (T7RA.HM) Income Statement Analysis – Financial Results
- Thermador Groupe SA (THEP.PA) Income Statement Analysis – Financial Results
- The a2 Milk Company Limited (ATM.NZ) Income Statement Analysis – Financial Results
- Nan Yang Dyeing & Finishing Co.,Ltd (1410.TW) Income Statement Analysis – Financial Results
- Tips Films Limited (TIPSFILMS.BO) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
| Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
| General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
| SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
| Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
| Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
| Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
| Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
| EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
| EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
| Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
| Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
| Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
| Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
| Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Oct. 3, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Taysha Gene Therapies,...
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges with study design feasibility for potential Biologics License Application (BLA) submission
2 Healthcare Stocks That More Than Tripled Recently. Can They Keep Climbing?
Canopy Growth jettisoned its unprofitable dietary supplements business and gained some investors' confidence in the process. Taysha Gehe Therapies more than quadrupled in response to a positive early result from an ongoing clinical trial.
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TSHA's 50-day simple moving average broke out above its 200-day moving average; this is known as a...
3 Small-Cap Stocks to Sell in September Before They Crash & Burn
The market had a choppy August as traders digested the latest developments from a busy earnings season and a hawkish Federal Reserve. While the overall market is volatile, we've seen some large speculative run-ups amid small-cap stocks.
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition
Flying below the radar on August 22nd: Two growth stocks about to take off
Investing in growth stocks can be an extremely profitable strategy if you buy in early. However, this also comes with a high risk that the investment may not pay off.
GordonMD® Invests in Private Placement for Taysha Gene Therapies
DALLAS--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...
Source: https://incomestatements.info
Category: Stock Reports